TY - JOUR
T1 - Expression of CD2 in Acute Promyelocytic Leukemia Correlates with Short Form of PML-RARα Transcripts and Poorer Prognosis
AU - Lin, Pei
AU - Hao, Suyang
AU - Medeiros, L. Jeffrey
AU - Estey, Elihu H.
AU - Pierce, Sherry A.
AU - Wang, Xuemei
AU - Glassman, Armand B.
AU - Bueso-Ramos, Carlos
AU - Huh, Yang O.
PY - 2004/3
Y1 - 2004/3
N2 - We studied the immunophenotype of 100 cases of acute promyelocytic leukemia (APL) with cytogenetic evidence of t(15;17)(q22;q21), 72 hypergranular (M3) and 28 microgranular (M3v), and correlated the results with molecular and clinical features. Most neoplasms (75/100 [75%]) had a typical immunophenotype: CD13+CD33+CD34-HLA-DR-. CD64, CD2, CD34, and HLA-DR were expressed in 27% (24/88), 23% (22/94), 21% (21/100), and 9% (9/98), respectively. CD34 expression was restricted to M3v; HLA-DR and CD2 were expressed more often in M3v than in M3 (P < .001). PML-RARα fusion transcripts were detected by reverse transcriptase-polymerase chain reaction in all 70 patients assessed. The short form of PML-RARα transcripts was found more frequently in M3v (P < .002) and CD2 + APL (P < .0001) than in M3 and CD2- APL, respectively. The median follow-up was 128 weeks. CD2+ APL was associated significantly with leukocytosis (P = .004), shorter complete remission duration (P =.03), and a trend toward shorter overall survival (P =.07) than CD2- APL. Overall survival for M3v vs M3 (P = .68) and short vs long transcripts (P = .21) was not significantly different. Immunophenotyping is useful for predicting the biologic and clinical behavior of APL.
AB - We studied the immunophenotype of 100 cases of acute promyelocytic leukemia (APL) with cytogenetic evidence of t(15;17)(q22;q21), 72 hypergranular (M3) and 28 microgranular (M3v), and correlated the results with molecular and clinical features. Most neoplasms (75/100 [75%]) had a typical immunophenotype: CD13+CD33+CD34-HLA-DR-. CD64, CD2, CD34, and HLA-DR were expressed in 27% (24/88), 23% (22/94), 21% (21/100), and 9% (9/98), respectively. CD34 expression was restricted to M3v; HLA-DR and CD2 were expressed more often in M3v than in M3 (P < .001). PML-RARα fusion transcripts were detected by reverse transcriptase-polymerase chain reaction in all 70 patients assessed. The short form of PML-RARα transcripts was found more frequently in M3v (P < .002) and CD2 + APL (P < .0001) than in M3 and CD2- APL, respectively. The median follow-up was 128 weeks. CD2+ APL was associated significantly with leukocytosis (P = .004), shorter complete remission duration (P =.03), and a trend toward shorter overall survival (P =.07) than CD2- APL. Overall survival for M3v vs M3 (P = .68) and short vs long transcripts (P = .21) was not significantly different. Immunophenotyping is useful for predicting the biologic and clinical behavior of APL.
KW - Acute promyelocytic leukemia
KW - Immunophenotype
KW - PML-RARα
KW - RT-PCR
KW - Reverse transcriptase-polymerase chain reaction
UR - http://www.scopus.com/inward/record.url?scp=1542377671&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1542377671&partnerID=8YFLogxK
U2 - 10.1309/XC8P9M8NKQDT38LB
DO - 10.1309/XC8P9M8NKQDT38LB
M3 - Article
C2 - 15023045
AN - SCOPUS:1542377671
SN - 0002-9173
VL - 121
SP - 402
EP - 407
JO - American journal of clinical pathology
JF - American journal of clinical pathology
IS - 3
ER -